Unravel the complexities of genetic research in neurodegenerative movement disorders. This track examines the fundamental genetic underpinnings of parkinson’s, huntington’s, and other conditions, with a focus on how genetics influences disease development and progression. Explore innovative therapeutic approaches, including gene-editing technologies like crispr, and the potential of gene therapies to modify disease outcomes. Ethical concerns surrounding genetic manipulation and testing will also be a key discussion point

Track 1-1: Genetic Mechanisms In Parkinson’s Disease

Track 1-2: Huntington’s Disease And Genetic Mutations

Track 1-3: Genomic Tools For Disease Diagnosis

Track 1-4: CRISPR And Gene Editing In Movement Disorders

Track 1-5: Ethical Considerations In Genetic Research

Delve into the latest research on genetic mechanisms, diagnostic tools, and the ethical challenges surrounding genetic manipulation, offering a deeper understanding of how genetic insights can pave the way for novel treatments.

This track focuses on the cognitive and behavioral impact of movement disorders. Cognitive decline, mood disorders, and other psychiatric symptoms often complicate the management of conditions like parkinson’s and huntington’s. Learn about the latest research on these aspects and how multidisciplinary approaches can optimize management strategies for affected individuals. Explore therapeutic innovations, including cognitive rehabilitation and pharmacological interventions designed to alleviate symptoms.

Track 2-1: Cognitive Decline in Parkinson’s disease

Track 2-2: Executive Function in Huntington’s disease

Track 2-3: Psychiatric Symptoms and Behavioral Disorders

Track 2-4: Assessment Tools For Cognitive Dysfunction

Track 2-5: Cognitive Rehabilitation Strategies

Through an in-depth exploration of cognitive impairments and behavioral symptoms, this track will examine how to improve patient outcomes with both clinical approaches and new therapeutic models.

Motor dysfunction is one of the most debilitating symptoms in movement disorders. This track will dive into the pathophysiology of tremors, rigidity, bradykinesia, and gait disturbances, providing insights into how these symptoms affect daily functioning. A significant portion will be dedicated to exploring current and emerging treatment strategies, aiming to improve mobility and reduce the physical burden on patients.

Track 3-1: Motor Symptoms in Parkinson’s Disease

Track 3-2: Gait and Postural Control in Movement Disorders

Track 3-3: Rigidity and Bradykinesia Mechanisms

Track 3-4: Tremor Management in Neurodegenerative Diseases

Track 3-5: Innovations in Motor Symptom Therapies

Explore therapeutic breakthroughs that are enhancing mobility and patient comfort, and delve into the ongoing research into symptom mechanisms to better target interventions.

Neuroimaging technologies are instrumental in tracking the progression of movement disorders. This track will cover the role of various imaging modalities in early diagnosis, disease progression, and treatment efficacy. From structural changes seen on MRI to the functional markers identified through PET and SPECT, participants will gain a comprehensive understanding of how neuroimaging supports personalized treatment plans.

Track 4-1: Structural Imaging in movement disorders

Track 4-2: Functional Imaging for Disease Progression

Track 4-3: Neuroimaging Biomarkers in Parkinson’s

Track 4-4: Imaging in Huntington’s Disease

Track 4-5: MRI and PET in Treatment Planning

Discover how neuroimaging helps clinicians tailor treatment approaches based on individualized brain imaging, opening new pathways for precision medicine in movement disorders.

Neurophysiological assessments offer a non-invasive, real-time view into the workings of the nervous system in individuals with movement disorders. This track explores the use of techniques like electromyography and transcranial magnetic stimulation to monitor disease progression, inform diagnosis, and refine therapeutic strategies. With a focus on practical applications, attendees will gain valuable insight into how these methods shape clinical decision-making.

Track 5-1: Electromyography in Movement Disorders

Track 5-2: Electrophysiological Techniques in Parkinson’s Disease

Track 5-3: Neurophysiological Markers of Disease Progression

Track 5-4: Transcranial Magnetic Stimulation Applications

Track 5-5: Neurophysiology in Neurodegenerative Diagnostics

Engage in an exploration of how electrophysiological markers can complement traditional diagnostic techniques, providing clinicians with new ways to monitor and manage movement disorders.

Neuromodulation Therapies, including Deep Brain Stimulation (DBS) and Deep Brain Stimulation (TMS), are rapidly gaining prominence as treatments for movement disorders. This track focuses on the clinical application and outcomes of these therapies, as well as the potential for emerging neuromodulation methods to enhance patient care.

Track 6-1: Deep Brain Stimulation in Movement Disorders

Track 6-2: Non-Invasive Neuromodulation in Huntington’s Disease

Track 6-3: Brain Stimulation for Dyskinesia Control

Track 6-4: Transcranial Magnetic Stimulation for Motor Symptoms

Track 6-5: Future Directions in Neuromodulation

This track offers a deep dive into the role of neuromodulation in treating movement disorders, providing a clear picture of its current applications and future possibilities.

Movement disorders are often complicated by atypical presentations and overlapping symptoms. This track will cover syndromes such as multiple system atrophy and progressive supranuclear palsy, focusing on their complex diagnosis and management. Special emphasis will be placed on how to differentiate these syndromes from more common movement disorders to ensure accurate treatment approaches.

Track 7-1: Parkinson’s Disease Plus Syndromes

Track 7-2: Progressive Supranuclear Palsy

Track 7-3: Multiple System Atrophy Mechanisms

Track 7-4: Corticobasal Degeneration and Motor Control

Track 7-5: Diagnostic Approaches for Atypical Syndromes

Understand the challenges and nuances in diagnosing rare movement disorders, as well as the evolving treatment options for these complex cases.

As the quest for disease-modifying treatments intensifies, neuroprotective therapies are at the forefront of research. This track will cover the mechanisms of neuroprotection in movement disorders, including the use of antioxidants, inflammation modulation, and regenerative approaches like stem cell therapy. Attendees will also learn about new drug development efforts aimed at halting disease progression.

Track 8-1: Antioxidant Therapies in Movement Disorders

Track 8-2: Neuroinflammation Modulation

Track 8-3: Gene Therapy as A Neuroprotective Strategy

Track 8-4: Stem Cell Therapies for Neuroprotection

Track 8-5: Emerging Drug-Based Neuroprotective Strategies

Gain an understanding of the potential and challenges of neuroprotective agents, and how they may contribute to slowing disease progression in neurodegenerative movement disorders.

Parkinsonism encompasses a range of syndromes, each with distinct characteristics. This track will focus on identifying and treating various subtypes, exploring the different clinical presentations and their implications for diagnosis and management. Attendees will gain a better understanding of these subtypes and how to approach their treatment.

Track 9-1: Atypical Parkinsonism Syndromes

Track 9-2: Diagnosis of Parkinson’s Plus Syndromes

Track 9-3: Differential Diagnosis in Parkinsonism

Track 9-4: Treatment Approaches for Parkinson’s Subtypes

Track 9-5: Genetic Markers in Parkinsonism

This track will emphasize the importance of accurate diagnosis and personalized management strategies for the diverse spectrum of Parkinsonism-related disorders.

Dyskinesia remains one of the most challenging symptoms of parkinson’s and huntington’s diseases. This track will cover the latest strategies for managing dyskinesia, focusing on both pharmacological and surgical approaches. Attendees will explore innovative treatments and the importance of a personalized, patient-centered approach to managing this complex symptom.

Track 10-1: Medical Management of Dyskinesia

Track 10-2: Surgical Options for Dyskinesia Control

Track 10-3: Neurostimulation for Dyskinesia Treatment

Track 10-4: Patient-Centered Approaches to Dyskinesia

Track 10-5: Future Directions in Dyskinesia Therapy

By highlighting a range of treatment options and strategies, this track aims to offer practical solutions for managing dyskinesia, ultimately improving the patient experience.

Huntington’s disease involves both genetic and environmental factors that contribute to its progression. This track will delve into the latest research on the disease's molecular mechanisms, examining the roles of protein aggregation, neuronal degeneration, and genetic mutations. Participants will explore advancements in identifying early biomarkers and potential therapies aimed at slowing or halting the disease’s course.

Track 11-1: Genetic Insights into Huntington’s Disease

Track 11-2: Neurodegenerative Mechanisms in Huntington’s Disease

Track 11-3: Cognitive and Psychiatric Complications in Huntington’s Disease

Track 11-4: Approaches to Targeted Treatments

Track 11-5: The Role of Clinical Trials in Huntington’s Disease

This track focuses on translating molecular understanding into therapeutic strategies and improving the diagnostic and treatment landscape for huntington’s disease.

Ataxia and Gait Abnormalities significantly affect the quality of life for individuals with movement disorders. This track will address the pathophysiological processes behind these Motor Symptoms, particularly in Parkinson’s and Huntington’s Diseases, and discuss the latest therapeutic and rehabilitative strategies aimed at improving mobility and independence.

Track 12-1: Understanding Ataxia in Neurodegenerative Disorders

Track 12-2: Mechanisms Behind Gait Disturbances in Parkinson’s Disease

Track 12-3: Cutting-edge Rehabilitation for Gait and Ataxia

Track 12-4: Impact of Assistive Technologies on Gait Disorders

Track 12-5: Diagnostic Innovations in Gait Assessment

This track will emphasize emerging diagnostic tools and rehabilitation techniques that are enhancing functional mobility in patients with movement disorders.

Dystonia, characterized by abnormal muscle contractions, presents unique challenges in diagnosis and treatment. This track will focus on the underlying neurological mechanisms that drive dystonia and explore both pharmacological and surgical approaches for managing this condition. Special attention will be given to the role of neurostimulation techniques and the latest advancements in botulinum toxin therapies.

Track 13-1: Pathophysiology of Dystonia

Track 13-2: Advances in Pharmacological Treatments for Dystonia

Track 13-3: Botulinum Toxin in the Treatment of Dystonia

Track 13-4: Surgical Approaches and Deep Brain Stimulation

Track 13-5: Emerging Therapies for Dystonia Management

This track will provide a comprehensive understanding of dystonia’s complexities and how the latest treatments are offering new hope for patients.

Spasticity is a common and disabling symptom in many movement disorders. This track will explore the latest advancements in managing spasticity, from pharmacological treatments to rehabilitation strategies. Attendees will learn about the role of neuromodulation and the integration of multi-disciplinary approaches to enhance functional recovery and improve patient outcomes.

Track 14-1: Pharmacological Interventions for Spasticity

Track 14-2: The Role of Botulinum Toxin and Other Injections

Track 14-3: Neuromodulation Techniques for Spasticity Control

Track 14-4: Surgical Management of Severe Spasticity

Track 14-5: Rehabilitation Strategies to Reduce Spasticity

This track will provide detailed insights into personalized spasticity management, focusing on improving quality of life through innovative treatments.

Deep Brain Stimulation (DBS) has revolutionized the treatment of movement disorders, particularly in Parkinson’s Disease and dystonia. This track will examine the latest advancements in DBS technology, including new surgical techniques, patient selection criteria, and long-term outcome data. The role of personalized DBS approaches will be discussed, focusing on optimizing therapeutic outcomes for patients.

Track 15-1: Personalized DBS Approaches in Parkinson’s Disease

Track 15-2: Innovations in DBS Technology and Surgery

Track 15-3: DBS for Dystonia and Essential Tremor

Track 15-4: Long-Term Outcomes of DBS Therapy

Track 15-5: Targeting Specific Brain Regions in DBS

This track will highlight how DBS is evolving as a treatment, including emerging technologies and its expanded use in various movement disorders.

Cerebellar disorders, such as ataxia and tremor, significantly affect motor control and coordination, presenting diagnostic challenges. This track will explore the pathophysiology of cerebellar disorders, including their impact on movement, cognition, and overall function. Attendees will also discuss novel treatments and rehabilitation strategies aimed at improving patient outcomes.

Track 16-1: Pathophysiology of Cerebellar Ataxia

Track 16-2: Diagnosing Cerebellar Disorders in Clinical Practice

Track 16-3: Pharmacological and Surgical Treatment Options

Track 16-4: Rehabilitation Approaches for Cerebellar Dysfunction

Track 16-5: Cerebellar Involvement in Neurodegenerative Diseases

This track will provide a comprehensive look into the cerebellum's role in movement disorders and the latest strategies to address these challenges.

Neurorehabilitation is crucial for improving functional independence in patients with movement disorders. This track will examine the latest rehabilitative techniques, including motor training, cognitive rehabilitation, and assistive technologies, focusing on personalized treatment plans for better patient outcomes.

Track 17-1: Neurorehabilitation for Parkinson’s Disease

Track 17-2: Cognitive Rehabilitation in Movement Disorders

Track 17-3: Role of Exercise In Improving Motor Function

Track 17-4: Assistive Technologies and Devices

Track 17-5: Rehabilitative Approaches for Huntington’s Disease

This track will emphasize the importance of personalized rehabilitation strategies in improving the quality of life for individuals with movement disorders.

Behavioral Neurology plays a critical role in the management of psychiatric and cognitive symptoms associated with movement disorders. This track will explore how the integration of Behavioral Neurology enhances the treatment of these disorders, with a particular focus on managing cognitive decline, depression, and other neuropsychiatric symptoms.

Track 18-1: Neuropsychiatric Symptoms in Parkinson’s Disease

Track 18-2: Cognitive Decline and Dementia In Movement Disorders

Track 18-3: Psychiatric Management in Huntington’s Disease

Track 18-4: Neuropsychiatric Assessment Tools

Track 18-5: Emerging Treatments For Behavioral Symptoms

This track will offer an in-depth exploration of the role of behavioral neurology in managing the complex neuropsychiatric symptoms in movement disorders.

Biomarkers are essential for improving the diagnosis, prognosis, and treatment of movement disorders. This track will focus on the latest advances in identifying and validating biomarkers, from genetic markers to imaging and fluid-based biomarkers, and discuss their potential applications in clinical trials and daily practice.

Track 19-1: Blood and Genetic Biomarkers for Parkinson’s Disease

Track 19-2: Imaging Biomarkers in Huntington’s Disease

Track 19-3: Biomarkers for Disease Progression and Monitoring

Track 19-4: Biomarkers in Clinical Trials for movement disorders

Track 19-5: Challenges in Biomarker Validation

This track will explore the transformative role of biomarkers in precision medicine and their potential to enhance clinical outcomes for patients with movement disorders.

Neuroepidemiology plays a crucial role in understanding the distribution, determinants, and outcomes of movement disorders. This track will examine global trends in the prevalence and incidence of Parkinson’s disease, Huntington’s disease, and other movement disorders, focusing on social, environmental, and genetic factors that influence disease development.

Track 20-1: global epidemiology of Parkinson’s disease

Track 20-2: environmental and genetic risk factors

Track 20-3: gender differences in movement disorder prevalence

Track 20-4: epidemiological trends in rare movement disorders

Track 20-5: the impact of public health initiatives on movement disorders

This track will provide valuable insights into the global landscape of movement disorders, highlighting the epidemiological factors that affect their prevalence and progression.

Pharmacological advancements are pivotal in improving the management of movement disorders. This track will focus on the latest drug developments, treatment regimens, and the role of pharmacogenomics in optimizing therapy for Parkinson’s, Huntington’s, and other neurodegenerative diseases.

Track 21-1: New Medications for Parkinson’s Disease

Track 21-2: Novel Drug Delivery Systems

Track 21-3: Pharmacogenomics and Personalized Treatment

Track 21-4: Emerging Pharmacological Therapies for Movement Disorders

Track 21-5: Managing Drug Side Effects and Interactions

This track will provide updates on the evolving pharmacological landscape and its potential to improve clinical outcomes for individuals with movement disorders.

Gene-based and molecular therapies are revolutionizing the treatment landscape for movement disorders. This track will explore gene therapy, molecular techniques such as CRISPR, and other cutting-edge approaches that hold promise for halting or reversing disease progression.

Track 22-1: Gene Therapy for Parkinson’s Disease

Track 22-2: Viral Vectors and Molecular Therapeutics

Track 22-3: Antisense Oligonucleotides in Huntington’s Disease

Track 22-4: CRISPR and Gene Editing Technologies

Track 22-5: Clinical Trials of Molecular Therapies

This track will delve into the forefront of molecular medicine and its potential to transform the treatment of neurodegenerative diseases.

Autonomic Dysfunctions is a common yet underexplored aspect of movement disorders. This track will focus on the various Autonomic Dysfunctions—such as gastrointestinal, cardiovascular, and sleep disturbances—that occur in Parkinson’s, Huntington’s, and other neurodegenerative conditions.

Track 23-1: Autonomic Dysfunctions in Parkinson’s Disease

Track 23-2: Gastrointestinal and Cardiovascular Autonomic Issues

Track 23-3: Sleep Disturbances and Autonomic Dysfunction

Track 23-4: Managing Autonomic Symptoms in Movement Disorders

Track 23-5: New Approaches to Autonomic Dysfunction Treatment

This track will shed light on the often-overlooked but significant autonomic issues that impact the lives of patients with movement disorders.

Clinical trials are central to advancing treatments for movement disorders. This track will highlight on-going and emerging clinical trials, with a focus on novel therapies, patient populations, and the future of clinical research in Parkinson’s, Huntington’s, and related diseases.

Track 24-1: Current Clinical Trials in Parkinson’s Disease

Track 24-2: New Approaches in Huntington’s Disease Trials

Track 24-3: Emerging Therapies in Dystonia and Tremor

Track 24-4: Gene Therapy Clinical Trials

Track 24-5: Evaluating Novel Interventions in Movement Disorders

This track will offer participants the latest updates on clinical research and emerging therapies, providing a glimpse into the future of movement disorder treatments.

Case Reports and series offer invaluable real-world insights into the clinical presentation, diagnosis, and treatment of movement disorders. This track will emphasize the importance of documenting and analyzing these cases to improve clinical understanding and patient care.

Track 25-1: Rare and Complex Movement Disorders

Track 25-2: Long-Term Case Series and Their Insights

Track 25-3: Case-Based Approaches to Diagnosis and Treatment

Track 25-4: Learning from Difficult or Unusual Cases

Track 25-5: Integrating Case Reports in Clinical Practice

This track will highlight the importance of case-based learning, showcasing how individual patient stories contribute to the broader knowledge of movement disorders.